Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
NCT06797375
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematologic Diseases
Autoimmune Diseases
Interventions
DRUG:
RLYB116 for Injection
Sponsor
Rallybio